THE coronavirus disease 2019 (COVID-19) pandemic has been an unprecedented global health crisis that has severely challenged the provision of routine healthcare, including screening for colorectal cancer (CRC).

TILL MAY 31, St. Luke’s Medical Center (SLMC) is offering a women’s health package at P11,920. The executive checkup, available at the Health and Wellness Center of SLMC Bonifacio Global City (Taguig City), includes the following: pap smear, gyne ultrasound, breast ultrasound, complete blood count, chest X-ray, urinalysis, fecalysis, nutritional counseling, and a complimentary outpatient COVID-19 RT-PCR test.

THE PRENATAL package of Makati Medical Center (MakatiMed) includes outpatient laboratory and ultrasound procedures, including an anti-HBS test, blood typing, congenital anomaly scan, glucose tolerance test, hepatitis B serologic test, HIV screening test, transvaginal or pelvic ultrasound, and urinalysis.

It was a historic day when President Rodrigo R. Duterte signed the Universal Health Care (UHC) Law in February 2019. The landmark legislation expands access to health services by automatically enrolling all Filipinos in the National Health Insurance Program. The law aims to provide all Filipinos with equitable access to quality and affordable healthcare services while being protected against financial risks. However, a little over a year later, the coronavirus disease 2019 (COVID-19) pandemic happened, severely affecting the global economy and overwhelming health systems in many countries, including some of the world’s wealthiest nations.

COLORECTAL CANCER is the third deadliest cancer in the Philippines after breast cancer and lung cancer. It is, however, beatable, treatable, and preventable, according to Dr. Atenodoro “Jun” R. Ruiz, Jr., head of The Medical City’s (TMC) colorectal cancer screening task force, at a discussion organized by TMC’s Augusto P. Sarmiento Cancer Institute.

IN LINE with Philippine Digestive Health Week (PDHW), ongoing till March 13, here are initiatives to increase digestive health screening and improve patient outcomes.

As part of a science-driven industry, the biopharmaceutical industry is leading the way in developing treatments, vaccines, and diagnostics for coronavirus disease 2019 (COVID-19). Our scientists are searching for potentially useful assets that can help with the development of new or repurposed treatments or vaccines to fight against the novel coronavirus. We are leveraging our manufacturing technologies to allow the rapid upscaling of production once a medicine or vaccine candidate is identified to meet the needs of the most affected populations. Phase 3 clinical trials are being conducted to establish safety and efficacy. We are collaborating with governments, global health and research organizations, and pharmaceutical laboratories to share knowledge, libraries, and technologies.

Moderna Inc said on Saturday it has agreed to supply the Philippines government 13 million doses of its COVID-19 vaccine, with deliveries set to...

The US National Institutes of Health (NIH) said on Tuesday that it has halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) symptoms as it was unlikely to benefit this group.

SHARPENING the focus on overseas Filipino workers (OFWs), senior citizens, persons with disabilities (PWDs), and blue-collar workers will improve population health outcomes, according to Hilton Y. Lam, director of the University of the Philippines’ Institute of Health Policy and Development Studies (IHPDS).

PROJECT MOSES, a health dashboard, aims to address misconceptions and streamline information for Filipinos seeking answers to their coronavirus disease 2019 (COVID-19) concerns.

With more patients in need of help to access treatments, advocates welcome the recent announcement of the Department of Health (DoH) that it would allocate at least a P700-million annual budget to the cancer assistance fund.